Alan Mardinly, PhD
Chief Scientific Officer
Dr. Alan Mardinly is Chief Scientific Officer at Science Corp., and is a cofounder of the company. He co-leads Science’s biohybrid project with Dr. Kong. His focus is on optogenetic therapies for vision restoration and biohybrid brain implants.
Alan has more than 15 years of experience in neuroscience research, working across biology and neuroscience from stem cells to brain implants. He received his BA in Biology from the University of Chicago in 2006 and his PhD in neurobiology from Harvard University in 2013, where he studied how experience-induced transcriptional programs control synaptic plasticity in inhibitory neurons. Alan then went to UC Berkeley where he developed holographic optogenetic approaches to stimulate the brain with spatial and temporal precision. In 2019 he joined the leadership team at Neuralink before eventually departing in 2021 when he left to co-found Science.
